Chugai Pharmaceutical (4519 JP): Emicizumab Gets PDUFA Data
Chugai Pharmaceutical (4519 JP) announced on August 24th that the US FDA has accepted its Biologics License Application (BLA) for emicizumab (emi)...
244 Views
Chugai – Positive Data for Emicizumab from HAVEN 2
After Alecensa impressed in Phase III trials earlier this week, Chugai (4519 JP) had the added pleasure of seeing emicizumab do well in the second...
220 Views
Chugai Pharmaceutical: Update Ahead of Summer Data Releases
The excitement at Chugai Pharmaceutical (4519 JP) is palpable for all to see, and you quickly get the impression at any meeting that the company is...
142 Views
Chugai Pharmaceutical-Exceptionally Productive In-House R&D Driving Strong Growth
We publish an in-depth analysis of Chugai Pharmaceutical arriving at a DCF derived fair value of ¥ 4,200. Chugai’s strategic alliance with its...
199 Views
Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
AML represents one of the largest hematologic cancer populations with one of the worst survival rates. Global prevalence is expected to increase at...
518 Views